8 / 42
Confirmed Objective Response Rate
Assessed per RECIST v1.1 by blinded, independent central review.
Data cut-off: May 9, 2016.
0
10
20
30
40
50
60
Pembrolizumab Chemotherapy
ORR, % (95% CI)
Δ17%
P
= 0.0011
45%
28%
PR
CR
n = 6
n = 63
n = 41
n = 1
Reck M, et al. NEJM 2016
10,3 vs 6 months